Clinical Trial Update: Immune Globulin Subcutaenous (Human), 20% [Phase 2, Phase 3]

View source ↗

Summary

Phase 2 and Phase 3 trial updates for Immune Globulin Subcutaneous (Human), 20% in primary immunodeficiency diseases have completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• Immune Globulin Subcutaneous (Human), 20% (immune globulin subcutaneous (human), 20%)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Primary Immunodeficiency Diseases (PID) | Phase 2, Phase 3 | Status: COMPLETED